Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis

Trial Profile

A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms IMPROVE
  • Sponsors EMD Serono; Merck Serono
  • Most Recent Events

    • 12 Oct 2018 Results of a post-hoc analysis assessing the dynamics of pseudoatrophy in RRMS patients treated with Interferon (IFN) beta-1a or placebo, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Results of a post-hoc analysis assessing spatio-temporal characteristics of active MRI lesions, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top